Piñeyro G, Blier P
Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
J Pharmacol Exp Ther. 1996 Feb;276(2):697-707.
Our study was undertaken to characterize the functional properties of 5-hydroxytryptamine (5-HT)1D receptors in the rat midbrain raphe nuclei. In a first series of experiments, designed to assess whether 5-HT1D receptors are coupled to Gi/o proteins, the intracerebral injection of pertussis toxin into the dorsal raphe as well as incubation of midbrain raphe slices with the alkylating agent N-ethyl-maleimide (NEM) reduced the efficacy of the 5-HT1B/1D agonist sumatriptan to inhibit the electrically evoked overflow of [3H]5-HT from preloaded slices. Furthermore, preincubation with NEM also reduced the efficacy with which the 5-HT1B/1D antagonist GR 127935 enhanced evoked overflow of [3H]5-HT. These results indicate that, in rat midbrain raphe nuclei, 5-HT1D receptors are linked to Gi/o proteins. In an attempt to determine whether 5-HT1D receptors are located on 5-HT neurons, the inhibitory effect of sumatriptan and of the nonselective 5-HT agonist 5-carboxyamidotryptamine on K(+)-evoked overflow of [3H]5-HT was assessed in the presence of the Na+ channel blocker tetrodotoxin. Neither the inhibitory effect of sumatriptan nor that of 5-carboxyamidotryptamine were reduced by the addition of tetrodotoxin to the superfusion medium, suggesting that these 5-HT1D receptors are located on 5-HT neurons and may be considered autoreceptors. In a third series of experiments, rats were treated for 21 days either with the selective 5-HT reuptake inhibitor paroxetine (10 mg/kg/day, s.c.) or the reversible type A monoamine oxidase inhibitor befloxatone (0.75 mg/kg/day, s.c.) and superfusion experiments were performed after a 48-hr washout period. 5-HT1D receptors, similarly to 5-HT1A autoreceptors, desensitize after long-term treatment with a selective 5-HT reuptake inhibitor or a reversible type A monoamine oxidase inhibitor because the efficacy of sumatriptan and of 8-OH-DPAT to inhibit the electrically evoked overflow of [3H]5-HT was reduced after the administration of either drug.
我们开展这项研究旨在表征大鼠中脑缝际核中5-羟色胺(5-HT)1D受体的功能特性。在第一组实验中,为评估5-HT1D受体是否与Gi/o蛋白偶联,向背侧缝际核脑内注射百日咳毒素以及将中脑缝际核脑片与烷基化剂N-乙基马来酰亚胺(NEM)共同孵育,均降低了5-HT1B/1D激动剂舒马曲坦抑制预加载脑片中电诱发的[3H]5-HT释放的效力。此外,用NEM预孵育也降低了5-HT1B/1D拮抗剂GR 127935增强[3H]5-HT诱发释放的效力。这些结果表明,在大鼠中脑缝际核中,5-HT1D受体与Gi/o蛋白相连。为确定5-HT1D受体是否位于5-HT能神经元上,在存在钠通道阻滞剂河豚毒素的情况下,评估了舒马曲坦和非选择性5-HT激动剂5-羧酰胺色胺对K(+)诱发的[3H]5-HT释放的抑制作用。向灌流液中添加河豚毒素,既未降低舒马曲坦的抑制作用,也未降低5-羧酰胺色胺的抑制作用,这表明这些5-HT1D受体位于5-HT能神经元上,可被视为自身受体。在第三组实验中,给大鼠连续21天皮下注射选择性5-HT再摄取抑制剂帕罗西汀(10 mg/kg/天)或可逆性A型单胺氧化酶抑制剂贝氟沙酮(0.75 mg/kg/天),在48小时洗脱期后进行灌流实验。与5-HT1A自身受体类似,5-HT1D受体在用选择性5-HT再摄取抑制剂或可逆性A型单胺氧化酶抑制剂长期治疗后会脱敏,因为在给予这两种药物后,舒马曲坦和8-OH-DPAT抑制电诱发的[3H]5-HT释放的效力均降低。